Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors
| Autor: | Qingmiao Yang, Huimin Hu, Dongsheng Huang, Yanan Gao, Jing Li, Weiling Zhang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Anthracycline 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences 0302 clinical medicine Neoplasms Natriuretic Peptide Brain Medicine Humans Anthracyclines Solid tumor Child Creatine Kinase Anthracycline Antibiotics Cardiotoxicity business.industry Infant Stroke Volume Hematology ANT Peptide Fragments Oncology 030220 oncology & carcinogenesis Child Preschool Pediatrics Perinatology and Child Health Female business N-terminal pro-Brain Natriuretic Peptide |
| Zdroj: | Pediatric hematology and oncology. 35(2) |
| ISSN: | 1521-0669 |
| Popis: | To investigate the cardiotoxicity indexes in children with malignant tumors after the administration of anthracycline (ANT) chemotherapy.Data from 131 children with malignant tumors who were treated using ANT chemotherapy at our hospital from January 2011 to December 2015 were collected to analyze the serologic indexes (such as N-terminal pro-brain natriuretic peptide [NT-proBNP] and isoenzyme of creatine kinase [CK-MB]) and changes in corrected QT interval(QT-c) and left ventricular ejection fraction (LVEF) before and after treatment with different ANT cumulative doses.General clinical data revealed that 2 of the 131 children developed clinical cardiotoxicity. The ANT cumulative dose range was 12-697 mg/mNT-proBNP showed significant changes when the ANT dose was200 mg/m |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |